Comment

. 2022 Feb;175(2):JC17.

doi: 10.7326/J21-0019. Epub 2022 Feb 1.

In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d

Behnood Bikdeli¹, David A Garcia²

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (B.B.).
² University of Washington, Seattle, Washington, USA (D.A.G.).

PMID: 35099994
DOI: 10.7326/J21-0019

Comment

In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d

Behnood Bikdeli et al. Ann Intern Med. 2022 Feb.

. 2022 Feb;175(2):JC17.

doi: 10.7326/J21-0019. Epub 2022 Feb 1.

Authors

Behnood Bikdeli¹, David A Garcia²

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (B.B.).
² University of Washington, Seattle, Washington, USA (D.A.G.).

PMID: 35099994
DOI: 10.7326/J21-0019

Abstract

Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181:1612-20. 34617959.

PubMed Disclaimer

Comment on

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI; HEP-COVID Investigators. Spyropoulos AC, et al. JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203. JAMA Intern Med. 2021. PMID: 34617959 Free PMC article. Clinical Trial.

Similar articles

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI; HEP-COVID Investigators. Spyropoulos AC, et al. JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203. JAMA Intern Med. 2021. PMID: 34617959 Free PMC article. Clinical Trial.
In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.
Bikdeli B, Garcia DA. Bikdeli B, et al. Ann Intern Med. 2022 Feb;175(2):JC16. doi: 10.7326/J21-0020. Epub 2022 Feb 1. Ann Intern Med. 2022. PMID: 35099997
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
Di Micco P, Imbalzano E, Russo V, Attena E, Mandaliti V, Orlando L, Lombardi M, Di Micco G, Camporese G, Annunziata S, Piccinocchi G, Pacelli W, Del Guercio M. Di Micco P, et al. Viruses. 2021 Dec 11;13(12):2486. doi: 10.3390/v13122486. Viruses. 2021. PMID: 34960754 Free PMC article. Review.
[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].
Vazquez FJ, Korin J, Baldessari EM, Capparelli FJ, Gutierrez P, Pale C, Bocanegra F, Grand B, Penchasky D, Gonzalez Alcántara MM, Prémoli MS, Tabares A, Wainsztein N, Odetto D, Vaccaro C, Martínez Aquino E, Cumpian O, Falabella V, Antuel García S, Saadi J, Siccardi M, Gándara E. Vazquez FJ, et al. Medicina (B Aires). 2020;80 Suppl 3:65-66. Medicina (B Aires). 2020. PMID: 32658849 Spanish.
Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.
Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Fontana P, et al. Swiss Med Wkly. 2020 Jun 21;150:w20301. doi: 10.4414/smw.2020.20301. eCollection 2020 Jun 15. Swiss Med Wkly. 2020. PMID: 32640479

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d

Affiliations

In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d

Authors

Affiliations

Abstract

Comment on

Similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Comment on

Similar articles

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical